Benlysta binds and neutralises the B cell survival factor BAFF, while rituximab targets CD20, a protein found on the surface of B cells. The anti-CD20 mechanism could also lead to some competition ...

like Benlysta when it was first launched, but GSK has since developed a formulation of its antibody that can be delivered subcutaneously with a pen injector. AZ is also working on a subcutaneous ...